Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT07627620
NCT07627620Not yet recruitingPhase 2

A Multi-Center Phase II Clinical Study of Camrelizumab Combined With Famitinib Malate and Platinum-based Chemotherapy in the Treatment of Recurrent/Metastatic Cervical Cancer

Hunan Cancer Hospital0 sites54 target enrollmentStarted: June 30, 2026Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Phase 2
Status
Not yet recruiting
Enrollment
54
Study OverviewStudy DesignEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

This study is an open-label, multi-center Phase II clinical study, aimed to evaluate the efficacy and safety of camrelizumab combined with famitinib malate and platinum-based chemotherapy in the treatment of recurrent/metastatic cervical cancer.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to 75 Years (Adult, Older Adult)
Sex
Female
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Female aged 18-75 years.
  • •Histopathologically confirmed recurrent/metastatic cervical squamous cell carcinoma, adenocarcinoma or adenosquamous cell carcinoma that cannot be radically treated by surgery, radiotherapy or chemoradiotherapy.
  • •No prior systemic anti-cancer therapy for recurrent/metastatic disease.
  • •According to RECIST v1.1 criteria, the patient must have at least one measurable lesion.
  • •Able to normally swallow drug tablets
  • •Has adequate organ function.
  • •Willing to participate and able to comply with research programme requirements.
  • •Eastern Cooperative Oncology Group (ECOG) performance status of 0-
  • •Estimated life expectancy of more than 3 months.

Exclusion Criteria

  • •Has any malignancy <5 years prior to study entry.
  • •Known to have brain or meningeal metastasis.
  • •Known to have autoimmune disease.
  • •Received live vaccinations 4 weeks before randomization or during the study period.
  • •Known allergies and contraindications to the investigational drug or any of its components.

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Similar Trials

Recruiting
Phase 2
A Phase II Clinical Trial of SHR-1826 for Non-Small Cell Lung CancerNon-Small Cell Lung Cancer
NCT07489716Suzhou Suncadia Biopharmaceuticals Co., Ltd.90
Not yet recruiting
Phase 2
A Prospective, Single-arm, Phase II Clinical Trial of Becotatug Vedotin for Injection Combined With Pucotenlimab Injection as a First-line Treatment for Platinum-intolerant Advanced Head and Neck Squamous Cell CarcinomaHNPCC
NCT07628855Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center30
Recruiting
Phase 3
A study evaluating the efficacy and safety of Pegozafermin for the treatment of liver fibrosis in adult participants with MASH (previously known as non-alcoholic steatohepatitis [NASH])
CTRI/2025/09/09524189bio, Inc.1,050
Not yet recruiting
Phase 1
Lisatoclax Plus R-CHOP or Pola-R-CHP in Untreated DLBCL: A Phase Ib/II Study
NCT07398638Sun Yat-sen University122
Recruiting
Phase 3
Study to evaluate efficacy and safety of Human normal immunoglobulin given in veins in patients with Immune thrombocytopenia (Low levels of the cells that help blood clot)
CTRI/2025/08/093411Bharat Serums and Vaccines Ltd30